SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Kilitch Drugs India informs about annual secretarial compliance report

27 May 2026 Evaluate
Pursuant to Regulation 24A of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, Kilitch Drugs India has enclosed Annual Secretarial Compliance Report for the financial year ended 31 March, 2026 issued by practicing company secretary, Deep Shukla & Associates dated 15th April, 2026.

The above information is a part of company’s filings submitted to BSE.

Kilitch Drugs(India) Share Price

185.30 2.95 (1.62%)
19-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1837.15
Dr. Reddys Lab 1271.55
Cipla 1353.85
Zydus Lifesciences 1070.90
Lupin 2351.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: